This article is more than 5 years old. Information may no longer be current.
Survey respondents would seek botulinum toxin lotion treatment for hyperhidrosis
Click Here to Manage Email Alerts
Survey participants who said they had hyperhidrosis indicated they would be willing to seek potential treatment with an experimental botulinum toxin lotion, according to product developer Anterios.
ANT-1207 is a botulinum toxin type A topical lotion under investigation as potential treatment for facial wrinkles, hyperhidrosis and other FDA-approved clinical indications for injectable botulinum, as well as new indications for acne, according to a press release.
Seventeen percent of survey respondents (n=2,599) indicated their antiperspirants were ineffective and that they sweat too much. On a self-scored Hyperhidrosis Disease Severity Scale, 3.2% of participants classified their hyperhidrosis as “moderate” or “severe.”
Of the participants reporting that they “sweat too much,” 54% of women and 37% of men indicated they would seek physician evaluation and possible ANT-1207 treatment if it were FDA-approved. Among patients who scored themselves as “having hyperhidrosis,” 74% of women and 67% of men said they would seek treatment, according to the release.
Underarms were the top location for treatment, followed by foreheads (45%) and groins (31%) for women and groins (43%) and forehead (41%) for men, the release said.
“The clinical trial results of ANT-1207 have been promising,” researcher William P. Coleman III, MD, dermatologist and clinical professor at Tulane University, said in the release. “The 3.2% incidence of hyperhidrosis … replicates very closely what was found in large published epidemiologic studies. While injectable botulinum is a highly effective treatment for hyperhidrosis and is approved by the FDA, it requires 30 to 40 needlesticks, which are a substantial barrier to treatment … . In clinical studies conducted to date, ANT-1207 shows clinical activity for 6 months from a single treatment, which would provide these patients with a significant window of relief.”
ANT-1207 is intended to be applied and massaged into patients’ skin for 10 minutes in a physician’s office, the release stated.